Evidence map›Paper›PMID 33219206›Full record

Trial reportBlood cancer journal2020

Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia.

Prateek Pophali, Aasiya Matin, Abhishek A Mangaonkar, Ryan Carr, Moritz Binder, Aref Al-Kali, Kebede H Begna, Kaaren K Reichard, Hassan Alkhateeb, Mithun V Shah and 4 more

Open access · goldAbstract readClinical TrialLetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Contemporary CMML Risk Stratification and Management.Current hematologic malignancy reports · 2025
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Prateek PophaliDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Aasiya MatinDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Abhishek A MangaonkarDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Ryan CarrDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Moritz BinderDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-9014-9658
Aref Al-KaliDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-0824-3715
Kebede H BegnaDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Kaaren K ReichardDivision of Hematopathology, Department of Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Hassan AlkhateebDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Mithun V ShahDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-5359-336X
Ayalew TefferiDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
William J HoganDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-5841-4105
Mark R LitzowDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Mrinal M PatnaikDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. patnaik.mrinal@mayo.edu.ORCID 0000-0001-6998-662X
Mayo Clinic · US

Funding

Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
NCATS NIH HHS UL1 TR002377
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hematopoietic Stem Cell TransplantationAdultAgedAllograftsDisease-Free SurvivalFemaleHumansLeukemia, Myelomonocytic, ChronicMaleMiddle AgedSurvival RateTime Factors

Identifiers

PMID33219206
PMCPMC7679455
OpenAlexW3104007886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.